Lantus Solostar Side Effects

Generic Name: insulin glargine

Note: This page contains information about the side effects of insulin glargine. Some of the dosage forms included on this document may not apply to the brand name Lantus Solostar.

Not all side effects for Lantus Solostar may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to insulin glargine: subcutaneous solution

In addition to its needed effects, some unwanted effects may be caused by insulin glargine (the active ingredient contained in Lantus Solostar). In the event that any of these side effects do occur, they may require medical attention.

You should check with your doctor immediately if any of these side effects occur when taking insulin glargine:

More common
  • Convulsions (seizures)
  • unconsciousness

If any of the following side effects occur while taking insulin glargine, check with your doctor or nurse as soon as possible:

More common
  • Low blood sugar, including anxious feeling; behavior change similar to being drunk; blurred vision; cold sweats; confusion; cool, pale skin; difficulty in thinking; dizziness or lightheadedness; drowsiness; excessive hunger; fast heartbeat; headache; nausea; nervousness; nightmares; restless sleep; shakiness; slurred speech; and tingling in the hands, feet, lips, or tongue
Less common or rare
  • Allergic reaction, including fast pulse, shortness of breath, skin rash or itching over the entire body, sweating, and wheezing

Some of the side effects that can occur with insulin glargine may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

Less common or rare
  • Bloating or swelling of face, hands, lower legs, and/or feet
  • depression of skin at injection site
  • injection site pain
  • local allergy, including itching, redness, or swelling at injection site
  • thickening of skin at injection site

For Healthcare Professionals

Applies to insulin glargine: subcutaneous solution

Cardiovascular

Cardiovascular side effects have included hyperinsulinemia. Given the high frequency of both microvascular and macrovascular diseases in patients with diabetes, some experts are evaluating insulin as a possible atherogenic agent. Controversy and continued study surround the role of hyperinsulinemia as the precursor of hypertension.[Ref]

Other cardiovascular risk factors that are accentuated in persons with carbohydrate intolerance and hypertension include abnormalities in platelet function, clotting factors, the fibrinolytic system, and dyslipidemia. The relationship between diabetes, insulin, and these disorders is currently under investigation.

Insulin may contribute to the pathogenesis of hypertension by stimulating the sympathetic nervous system, promoting renal sodium retention, and/or stimulating vascular smooth muscle hypertrophy. It may induce dyslipidemia by promoting hepatic synthesis of very low density lipoproteins (VLDLs).

Insulin may stimulate heart rate in the absence of hypoglycemia.[Ref]

Dermatologic

Dermatologic side effects have included lipohypertrophy (insulin is lipogenic) and lipoatrophy (probably immunologically-mediated). The incidence of lipoatrophy has been markedly decreased with the use of purer forms of pork insulin or biosynthetic human insulin and when injection sites were alternated. Without proper hygiene, subcutaneous insulin injections have been complicated by infection.[Ref]

Endocrine

Permanent neuropsychological impairment has been associated with recurrent episodes of severe hypoglycemia.

In one retrospective study of 600 randomly selected patients with insulin-treated diabetes mellitus, the only reliable predictors of severe hypoglycemia were a history of hypoglycemia, a history of hypoglycemia-related injury or convulsion, and the duration of insulin therapy. Those with a history of hypoglycemia had been treated with insulin for 17.4 years, which was significantly longer than the 14.3 years in the insulin-treated patients without a history of hypoglycemia.

Human insulin does not appear to be associated with hypoglycemic episodes more often than animal insulin. Caution is recommended when switching from animal (either bovine or pork) to purified porcine insulin or biosynthetic human insulin, however, because of increased potency or bioavailability.[Ref]

Endocrine side effects have included hypoglycemia, which has been the most common and serious side effect of insulin, occurring in approximately 16% of type 1 and 10% of type II diabetic patients (the incidence varies greatly depending on the populations studied, types of insulin therapy, etc). Although there are counterregulatory endocrinologic responses to hypoglycemia, some responses have been decreased, inefficient, or absent in some patients. Severe hypoglycemia has usually presented first as confusion, sweating, or tachycardia, and has resulted in coma, seizures, cardiac arrhythmias, neurological deficits, and death. Blood or urine glucose monitoring is recommended in patients who are at risk of hypoglycemia or who do not recognize the signs and symptoms of hypoglycemia. The risk for developing hypoglycemia has been higher in patients receiving intensive or continuous infusion insulin therapy. The association between insulin and dyslipidemia is currently being evaluated.[Ref]

Gastrointestinal

Gastrointestinal side effects have been reported rarely. GI distress has tended to resolve with dose reduction.[Ref]

General

Intensive insulin therapy causes an increase in body fat as a result of the elimination of glycosuria and reduction in 24-hour energy expenditure. The reduction in 24-h energy expenditure is the result of an insulin-associated decrease in triglyceride/free fatty acid cycling and nonoxidative glucose and protein metabolism.[Ref]

General side effects have included weight gain, which sometimes presented as edema associated with abrupt restoration of glucose control in a patient whose control was previously poor. Weight gain may have been due to more efficient use of calories during insulin therapy, suggesting additional benefits of dietary and exercise modifications. Patients on intensive insulin therapy have been more likely to experience weight gain.[Ref]

Hematologic

Hematologic side effects have included increased concentration of von Willebrand factor due to insulin-induced hypoglycemia . Increased von Willebrand factor, combined with hypoglycemia-associated decreased plasma volume and increased plasma viscosity, has predisposed patients to reduced peripheral perfusion or embolic phenomenon. A single case of insulin-induced hemolytic anemia has been reported.[Ref]

The effects of insulin-induced hypoglycemia on hemostasis may explain some of the clinical observations of embolic phenomenon during treatment of diabetic ketoacidosis.

Limited data show that diabetics have a significantly lower basal concentration of tissue plasminogen activator.[Ref]

Hypersensitivity

Hypersensitivity side effects have included both local and systemic reactions. These reactions have become rare (less than 1% of patients) due to the use of purer forms of pork insulin or biosynthetic human insulin. Local reactions have presented as erythema, swelling, heat, or subcutaneous nodules. They usually occurred within the first two weeks of therapy, then disappeared. True allergy to insulin has been rare, and sensitization was usually associated with specific animal proteins in bovine and less pure forms of porcine insulins.[Ref]

A diabetic patient with true allergy to insulin can undergo desensitization. Desensitization kits and protocols are available from some insulin manufacturers.[Ref]

Immunologic

Immunologic analysis of anaphylaxis to some insulin preparations in some cases has revealed markedly elevated serum levels of lgE and lgG to protamine, but not to regular insulin.[Ref]

Immunologic side effects have included the formation of anti-insulin antibodies, particularly when animal insulin formulations were used. The presence of these antibodies caused the elimination half-life of insulin to increase.[Ref]

Metabolic

Rare cases of hypophosphatemia have been associated with the use of glucose, insulin, and potassium infusions during the treatment of myocardial infarction.[Ref]

Metabolic side effects have included reports of hypokalemia and hypomagnesemia, particularly in patients treated for diabetic ketoacidosis (DKA). Insulin increases the intracellular transport of phosphate, which has often resulted in hypophosphatemia during treatment of DKA.[Ref]

Ocular

Ocular side effects have included reports of bilateral presyopia (blurry vision). This was thought to be due to changes in the osmotic equilibrium between the lens and the ocular fluids and was usually self-limited.[Ref]

Renal

Renal side effects have included significantly decreased renal plasma flow, glomerular filtration rate, and significantly increased urinary albumin excretion rate resulting from insulin-induced hypoglycemia These changes were usually reversible upon resolution of hypoglycemia.[Ref]

Hypoglycemia is associated with increased plasma dopamine, epinephrine, and plasma renin activity. Acute changes in renal function during insulin-induced hypoglycemia, therefore, may result from direct stimulation of the efferent sympathetic nerves to the kidney and hormonal counterregulatory mechanisms.[Ref]

References

1. Savage PJ, Soad MF "Insulin and atherosclerosis: villain bystander?" Br Heart J 69 (1993): 473-5

2. Koh H, Nambu S, Tsushima M, et al "The effects of insulin on the cardiovascular system in patients with coronary heart disease." Arzneimittelforschung 34 (1984): 185-90

3. Sowers JR, Standley PR, Ram JL, Jacober S, Simpson L, Rose K "Hyperinsulinemia factors in the pathogenesis of hypertension and atherosclerosis." Am J Hypertens 6 (1993): s260-70

4. Bressler R, Galloway JA "The insulins." Ration Drug Ther 5 (1971): 1-6

5. Collier A, Matthews DM, Young RJ, Clarke BF "Transient atrial fibrillation precipitated by hypoglycaemia: two case reports." Postgrad Med J 63 (1987): 895-7

6. Shinozaki K, Suzuki M, Ikebuchi M, Takaki H, Hara Y, Tsushima M, Harano Y "Insulin resistance associated with compensatory hyperinsulinemia as an independent risk factor for vasospastic angina." Circulation 92 (1995): 1749-57

7. Siani A, Strazzullo P, Giorgione N, et al "Insulin-induced increase in heart rate and its prevention by propranolol." Eur J Clin Pharmacol 38 (1990): 393-5

8. Jarrett RJ "Is insulin atherogenic?" Diabetologia 31 (1988): 71-5

9. Standl E "Hyperinsulinemia and atherosclerosis." Clin Invest Med 18 (1995): 261-6

10. Stern MP "Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents?" Ann Intern Med 124(1 Pt 2) (1996): 110-6

11. Hilsted J, Bonde-Petersen F, Norgaard M-B, et al "Haemodynamic changes in insulin-induced hypoglycaemia in normal man." Diabetologia 26 (1984): 328-32

12. Jarrett RJ "Insulin and atheroma." Lancet 05/30/87 (1987): 1272

13. Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980): 69-71

14. Patrick AW, Campbell IW "Fatal hypoglycaemia in insulin-treated diabetes mellitus: clinical features and neuropathological changes." Diabetic Med 7 (1990): 349-54

15. Swislocki A "Insulin resistance and hypertension." Am J Med Sci 300 (1990): 104-15

16. Vettor R, Mazzonetto P, Macor C, Scandellari C, Federspil G "Effect of endogenous organic hyperinsulinaemia on blood pressure and serum triglycerides." Eur J Clin Invest 24 (1994): 350-4

17. Bohrer H, Fleischer F, Krier C "Hyperkalemic cardiac arrest after cardiac surgery following high-dose glucose-insulin-potassium infusion for inotropic support." Anesthesiology 69 (1988): 949-53

18. Skyler JS "Human insulin after 10 years." Diabetes Care 16 Suppl 3 (1993): 1-3

19. Slater EE "Insulin resistance and hypertension." Hypertension 18 (1991): I108-14

20. Mann SJ, Krakoff LR "Hypertensive crisis caused by hypoglycemia and propranolol." Arch Intern Med 144 (1984): 2427-8

21. Tenkanen L, Manttari M, Manninen V "Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: experience from the helsinki heart study." Circulation 92 (1995): 1779-85

22. MacDonald MJ "Conventional and human insulin: complications of insulin therapy in children." Prim Care 10 (1983): 691-706

23. Takata S, Yamamoto M, Yagi S, et al "Peripheral circulatory effects of insulin in diabetes." Angiology Feb (1985): 110-5

24. Stout RW "Overview of the association between insulin and atherosclerosis." Metabolism 34 (1985): 7-12

25. Wheatley T, Edwards OM "Insulin oedema and its clinical significance: metabolic studies in three cases." Diabetic Med 2 (1985): 400-4

26. Pladziewicz DS, Nesto RW "Hypoglycemia-induced silent myocardial ischemia." Am J Cardiol 63 (1989): 1531-2

27. Genuth S "Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus." Ann Intern Med 124(1 Pt 2) (1966): 104-9

28. Scoppola A, Testa G, Frontoni S, Maddaloni E, Gambardella S, Menzinger G, Lala A "Effects of insulin on cholesterol synthesis in type II diabetes patients." Diabetes Care 18 (1995): 1362-9

29. Mantle JA, Rogers WJ, Smith LR, et al "Clinical effects of glucose-insulin-potassium on left ventricular function in acute myocardial infarction: results from a randomized clinical trial." Am Heart J 102 (1981): 313-24

30. Wieczorek I, Pell AC, McIver B, MacGregor IR, Ludlam CA, Frier BM "Coagulation and fibrinolytic systems in type I diabetes: effects of venous occlusion and insulin-induced hypoglycaemia." Clin Sci (Colch) 84 (1993): 79-86

31. Wingard DL, Barrettconnor EL, Ferrara A "Is insulin really a heart disease risk factor?" Diabetes Care 18 (1995): 1299-304

32. Gossain VV, Rovner DR, Mohan K "Systemic allergy to human (recombinant DNA) insulin." Ann Allergy 55 (1985): 116-8

33. Brown RT, Polinsky RJ, Baucom CE "Euglycemic insulin-induced hypotension in autonomic failure." Clin Neuropharmacol 12 (1989): 227-31

34. Reeves WG, Allen BR, Tattersall RB "Insulin-induced lipoatrophy: evidence for an immune pathogenesis." Br Med J 06/21/80 (1980): 1500-3

35. Brogden RN, Heel RC "Human insulin. A review of its biological activity, pharmacokinetics and therapeutic use." Drugs 34 (1987): 350-71

36. Pietri A, Raskin P "Cutaneous complications of chronic continuous subcutaneous insulin infusion therapy." Diabetes Care 4 (1981): 624-6

37. Chin RL, Martinez R, Garmel G "Gas gangrene from subcutaneous insulin administration." Am J Emerg Med 11 (1993): 622-5

38. Elte JW, van der Schroeff JG, van Leeuwen AW, Radder JK "Sclerosing granuloma after short-term administration of depot-insulin hoechst." Klin Wochenschr 60 (1982): 1461-4

39. Berman BA, Ross RN "Conversations on allergy and immunology: insulin hypersensitivity." Cutis 32 (1983): 320,28,30,32

40. Goldman JM, Wheeler MF "Lipodystrophy from recombinant DNA human insulin." Am J Med 83 (1987): 195-6

41. Johansen K, Ellegaard S, Wex S "Detection of nocturnal hypoglycemia in insulin-treated diabetics by a skin temperature-skin conductance meter." Acta Med Scand 220 (1986): 213-7

42. Valenta LJ, Elias AN "Insulin-induced lipodystrophy in diabetic patients resolved by treatment with human insulin." Ann Intern Med 102 (1985): 790-1

43. Schernthaner G "Immunogenicity and allergenic potential of animal and human insulins." Diabetes Care 16 Suppl 3 (1993): 155-65

44. Fleming MG, Simon SI "Cutaneous insulin reaction resembling acanthosis nigricans." Arch Dermatol 122 (1986): 1054-6

45. Lingenfelser T, Renn W, Sommerwerck U, Jung MF, Buettner UW, Zaiser-Kaschel H, Kaschel R, Eggstein M, Jakober B "Compromised hormonal counterregulation neurophysiological function after recurrent short-term episodes of insulin-induced hypoglycemia in IDDM patients." Diabetes 42 (1993): 610-8

46. Daniel DG, Rabin PL "Disguises of delirium." South Med J 78 (1985): 666-72

47. Walker JD, Viberti G "Recurrent nocturnal hypoglycemia in an insulin-dependent diabetic patient receiving a small daily dose of insulin." Am J Med 88 (1990): 537-9

48. Shimada R, Nakashima T, Nunoi K, et al "Arrhythmia during insulin-induced hypoglycemia in a diabetic patient." Arch Intern Med 144 (1984): 1068-9

49. Evans DJ, Pritchard-Jones K, Trotman-Dickenson B "Insulin oedema." Postgrad Med J 62 (1986): 665-8

50. Orchard TJ, Maser RE, Becker DJ, et al "Human insulin use and hypoglycaemia: insights from the pittsburgh epidemiology of diabetes complications study." Diabetic Med 8 (1991): 469-74

51. Bhatia V, Wolfsdorf JI "Severe hypoglycemia in youth with insulin-dependent diabetes mellitus: frequency and causative factors." Pediatrics 88 (1991): 1187-93

52. Kiser D "The somogyi effect." Am J Nurs Feb (1980): 236-8

53. Berger W, Honegger B, Keller U, Jaeggi E "Warning symptoms of hypoglycaemia during treatment with human and porcine insulin in diabetes mellitus." Lancet 05/13/89 (1989): 1041-4

54. Lingenfelser T, Renn W, Plonz C, et al "Catecholamine response during human and pork insulin-induced hypoglycemia in IDDM patients." Diabetes Care 15 (1992): 261-4

55. Garre M, Boles JM, Garo B, Mabin D "Cerebral oedema in diabetic ketoacidosis: do we use too much insulin?" Lancet 1 (1986): 220

56. Tzamaloukas AH, Avasthi PS "Hypoglycemia during hemodialysis in diabetics treated with insulin." Nephron 61 (1992): 470-1

57. Ziegler D, Hubinger A, Gries FA "Changes in brainstem auditory evoked potentials during insulin-induced hypoglycaemia in type 1 diabetic patients." Diabetic Med 8 (1991): 805-11

58. Krahn DD, Mackenzie TB "Organic personality syndrome caused by insulin-related nocturnal hypoglycemia." Psychosomatics 25 (1984): 711-2

59. Kidson W "The Somogyi effect. Has it ever existed and what harm has it caused?" Med J Aust 159 (1993): 480-2

60. Teuscher A, Reinli K "Severe hypoglycaemia in Diabetes Control and Complications Trial." Lancet 343 (1994): 1097-8

61. Urdl W, Desoye G, Schmon B, et al "Interactions between insulin and insulin-like growth factor I in the pathogenesis of polycystic ovarian disease." Ann N Y Acad Sci 626 (1991): 177-83

62. Stangenberg M, Persson B, Stange L, Carlstrom K "Insulin-induced hypoglycemia in pregnant diabetics." Acta Obstet Gynecol Scand 62 (1983): 249-52

63. Egger M, Smith GD, Teuscher A "Hypoglycaemia with human and porcine insulins." BMJ 306 (1993): 719-20

64. Block MB, Rubenstein AH "Spontaneous hypoglycemia in diabetic patients with renal insufficiency." JAMA 213 (1970): 1863-6

65. Wolf JP, Massol J, Nguyen NU, Berthelay S "Arginine vasopressin response to insulin-induced hypoglycemia in insulin-dependent diabetics with asymptomatic hypoglycemia." Horm Metab Res 22 (1990): 232-6

66. Coscelli C, Lostia S, Lunetta M, Nosari I, Coronel GA "Safety, efficacy, acceptability of a pre-filled insulin pen in diabetic patients over 60 years old." Diabetes Res Clin Pract 28 (1995): 173-7

67. Yoo J, Peter S, Kleinfeld M "Transient hypoglycemic hemiparesis in an elderly patient." J Am Geriatr Soc 34 (1986): 479-81

68. Caprio S, Amiel S, Tamborlane WV, et al "Defective free-fatty acid and oxidative glucose metabolism in IDDM during hypoglycemia." Diabetes 39 (1990): 134-41

69. Wredling R, Levander S, Adamson U, Lins PE "Permanent neuropsychological impairment after recurrent episodes of severe hypoglycaemia in man." Diabetologia 33 (1990): 152-7

70. Steel JM, Masterton G, Patrick AW, McGuire R "Hyperventilation or hypoglycaemia?" Diabetic Med 6 (1989): 820-1

71. Kalimo H, Olsson Y "Effects of severe hypoglycemia on the human brain." Acta Neurol Scand 62 (1980): 345-56

72. Brodows RG, Williams C, Amatruda JM "Treatment of insulin reactions in diabetics." JAMA 252 (1984): 3378-81

73. Boden G, Reichard GA, Hoeldtke RD, et al "Severe insulin-induced hypoglycemia associated with deficiencies in the release of counterregulatory hormones." N Engl J Med 305 (1981): 1200-5

74. Borch-Johnsen K, Helweg-Larsen K "Sudden death and human insulin: is there a link?" Diabet Med 10 (1993): 255-9

75. Hepburn DA, MacLeod KM, Pell AC, Scougal IJ, Frier BM "Frequency and symptoms of hypoglycaemia experienced by patients with type 2 diabetes treated with insulin." Diabet Med 10 (1993): 231-7

76. Bernstein RK "The somogyi phenomenon." Arch Intern Med 145 (1985): 575

77. Frier BM, Corrall RJ, Davidson NM, et al "Peripheral blood cell changes in response to acute hypoglycaemia in man." Eur J Clin Invest 13 (1983): 33-9

78. von Kriegstein E "Hypoglycaemia with human and porcine insulins." BMJ 306 (1993): 720

79. Kerr D, Reza M, Smith N, Leatherdale BA "Importance of insulin in subjective, cognitive, and hormonal responses to hypoglycemia in patients with IDDM." Diabetes 40 (1991): 1057-62

80. Reichard P, Britz A, Rosenqvist U "Intensified conventional insulin treatment and neuropsychological impairment." Br Med J 303 (1991): 1439-42

81. Fish HR, Chernow B, O'Brian JT "Endocrine and neurophysiologic responses of the pituitary to insulin-induced hypoglycemia: a review." Metabolism 35 (1986): 763-80

82. Tattersall RB, Gill GV "Unexplained deaths of type 1 diabetic patients." Diabetic Med 8 (1991): 49-58

83. Santiago JV "Intensive management of insulin dependent diabetes: risks, benefits, and unanswered questions." J Clin Endocrinol Metab 75 (1992): 977-82

84. MacLeod KM, Hepburn DA, Frier BM "Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients." Diabet Med 10 (1993): 238-45

85. Langan SJ, Deary IJ, Hepburn DA, Frier BM "Cumulative cognitive impairment following recurrent severe hypoglycaemia in adult patients with insulin-treated diabetes mellitus." Diabetologia 34 (1991): 337-44

86. Karam J, Brink S, Clements R, et al "Evaluation of efficacy and safety of human insulin (novo) in the treatment of insulin-dependent diabetes mellitus: a double-blind, multicenter clinical trial." Diabetes Care 6 (1983): 56-60

87. Arnqvist HJ, Halban PA, Mathiesen UL, Zahnd G, von Schenck H "Hypoglycaemia caused by atypical insulin antibodies in a patient with benign monoclonal gammopathy." J Intern Med 234 (1993): 421-7

88. Moses RG, Hubert PA, Lewis-Driver DJ "Severe hypoglycaemia: a one-year prospective survey in wollongong." Med J Aust 142 (1985): 294-6

89. Riddle MC "Relief of gastrointestinal symptoms by correcting insulin excess." Diabetes Care 4 (1981): 296-8

90. Carlson MG, Campbell PJ "Intensive insulin therapy and weight gain in IDDM." Diabetes 42 (1993): 1700-7

91. Yamreudeewong W, Cavell RM, Henann NE "Possible hemolytic anemia associated with human insulin therapy." DICP 24 (1990): 887

92. Fisher BM, Quin JD, Rumley A, et al "Effects of acute insulin-induced hypoglycaemia on haemostasis, fibrinolysis and haemorheology in insulin-dependent diabetic patients and control subjects." Clin Sci 80 (1991): 525-31

93. Fisher BM, Smith JG, McCruden DC, Frier BM "Responses of peripheral blood cells and lymphocyte subpopulations to insulin-induced hypoglycaemia in human insulin-dependent (type 1) diabetes." Eur J Clin Invest 17 (1987): 208-13

94. Diem P, Spengler H, De Weck AL "Lymphocyte transformation by insulin and insulin-zinc suspensions." Clin Exp Immunol 50 (1982): 155-62

95. Altman JJ, Pehuet M, Slama G, Tchobroutsky C "Three cases of allergic reaction to human insulin." Lancet 2 (1983): 524

96. Silverstone P "Generalised allergic reaction to human insulin." Br Med J 292 (1986): 933-4

97. Chideckel EW, Mullin CJ, Michael BE "Cimetidine in insulin allergy." Diabetes Care 4 (1981): 503-4

98. Wurzburger MI, Prelevic GM, Despotovic N, et al "Delayed-type allergy against various insulin preparations including human semisynthetic insulin." Ann Allergy 59 (1987): 44-7

99. Naparstek Y, Ben-Chetrit E, Okon E, Estrov Z, Eliakim M "Angioimmunoblastic lymphadenopathy in a patient with allergy to insulin: a case report." Cancer 47 (1981): 545-7

100. Stewart WJ, McSweeney SM, Kellett MA, et al "Increased risk of severe protamine reactions in NPH insulin-dependent diabetics undergoing cardiac catheterization." Circulation 70 (1984): 788-92

101. Small P, Lerman S "Human insulin allergy." Ann Allergy 53 (1984): 39-41

102. Simmonds JP, Russell GI, Cowley AJ, et al "Generalised allergy to porcine and bovine monocomponent insulins." Br Med J 08/02/80 (1980): 355-6

103. Burcelin RG, Eddouks M, Beylot M, Normand S, Boitard C, Feutren G, Landais P, Riou JP, Girard JR, Bach JF, et al "Hypersensitivity to insulin during remissions in cyclosporin-treated IDDM patients." Diabetes Care 16 (1993): 881-8

104. Ross JM, Murali MR, DeLara TC, Cheron RG "Anaphylaxis and immunologic insulin resistance in a diabetic woman with ketoacidosis." Diabetes Care 7 (1984): 276-9

105. Carveth-Johnson AO, Mylvaganam K, Child DF "Generalised allergic reaction with synthetic human insulin." Lancet 12/04/82 (1982): 1287

106. Lyngsoe J, Vestermark S "The efficacy and safety of human insulin (novo) in insulin-dependent diabetic patients." Diabetes Care 6 (1983): 53-5

107. Thompson DM, Ronco JJ "Prolonged desensitization required for treatment of generalized allergy to human insulin." Diabetes Care 16 (1993): 957-8

108. Goldman JM, Brynildsen HC "Generalised allergy to porcine and bovine monocomponent insulins." Br Med J 281 (1980): 1494

109. Jovanovic-Peterson L, Sparks S, Palmer JP, Peterson CM "Jet-injected insulin is associated with decreased antibody production and postprandial glucose variability when compared with needle- injected insulin in gestational diabetic women." Diabetes Care 16 (1993): 1479-84

110. Kahn CR, Mann D, Rosenthal AS, et al "The immune response to insulin in man: interaction of HLA alloantigens and the development of the immune response." Diabetes 31 (1982): 716-23

111. Micic D, Brkic S, Kendereski A, Popovic V, Zoric S, Nikolic JA, Igrutinovic L, Ivanoska D, Manojlovic D, Micic J "Immunological resistance to human biosynthetic insulin--effects of immunosuppression and plasmapheresis." Diabetes Res Clin Pract 19 (1993): 83-9

112. Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,

113. Dykewicz MS, Kim HW, Orfan N, Yoo TJ, Lieberman P "Immunologic analysis of anaphylaxis to protamine component in neutral protamine Hagedorn human insulin." J Allergy Clin Immunol 93 (1994): 117-25

114. Marwick TH, Woodhouse SP "Severe hypophosphataemia induced by glucose-insulin-potassium therapy. A case report and proposal for altered protocol." Int J Cardiol 18 (1988): 327-30

115. Sjolie AK "Ocular complications in insulin treated diabetes mellitus." Acta Ophthalmol (Copenh) S172 (1985): 1-77

116. Frier BM, Hepburn DA, Fisher BM, Barrie T "Fall in intraocular pressure during acute hypoglycaemia in patients with insulin dependent diabetes." Br Med J 294 (1987): 610-1

117. Patrick AW, Hepburn DA, Swainson CP, Frier BM "Changes in renal function during acute insulin-induced hypoglycaemia in patients with type 1 diabetes." Diabetic Med 9 (1992): 150-5

118. Christensen CK, Christiansen JS, Christensen T, et al "The effect of six months continuous subcutaneous insulin infusion on kidney function and size in insulin-dependent diabetics." Diabetic Med 3 (1986): 29-32

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web4)